TY  - JOUR
AU  - Alvarez-Lopez, I
AU  - Bezares, S
AU  - Dalmau Portulas, E
AU  - Garcia-Martinez, E
AU  - García-Sáenz, J Á
AU  - Gil-Gil, M
AU  - Martinez de Dueñas, E
AU  - Ribelles, N
AU  - Santaballa Bertran, A
PY  - 2020
DO  - 10.1007/s12094-019-02269-7
UR  - http://hdl.handle.net/10668/15098
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormone...
LA  - en
KW  - Consensus
KW  - Hormonal receptor
KW  - Hormonal resistance
KW  - Hormonal therapy
KW  - Luminal
KW  - Metastatic breast cancer
KW  - Aged
KW  - Antineoplastic Agents, Hormonal
KW  - Biomarkers, Tumor
KW  - Biopsy
KW  - Breast
KW  - Breast Neoplasms
KW  - Clinical Decision-Making
KW  - Consensus
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Gene Expression
KW  - Humans
KW  - Immunohistochemistry
KW  - Ki-67 Antigen
KW  - Menopause
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - Neoplasm Recurrence, Local
KW  - Neoplasms, Hormone-Dependent
KW  - Ovary
KW  - Practice Guidelines as Topic
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
TI  - Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.
TY  - research article
VL  - 22
ER  -